Base to Base biotech podcast 11: Turning cancer into a chronic disease, and a different way to draw blood

This week, we have a conversation with Ben Zeskind, CEO and co-founder of Immuneering, and a discussion with Tasso Inc.’s co-founder and chief technology officer, Erwin Berthier.

Interview times:

01:27 Tasso

27:25 Immuneering

Immuneering

There is no cure for HIV, yet many people with the virus now live long, healthy lives – thanks to available medicines that prevent disease progression with minimal side effects, treating HIV almost like a chronic condition.

So why don’t we treat cancer the same way?

Curing cancer is seen as the gold standard in medicine, with many drugs focused on shrinking tumours as aggressively as possible – often at the expense of patient tolerability and quality of life. One widely used class of cancer drugs known as MEK inhibitors work by turning of ...